The Form 4 filing, an SEC report of insider stock activity, was submitted on November 2, 2026. It covers trades made on October 30, 2026, by Martine A. Rothblatt, United Therapeutics' chairperson and chief executive.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-30 |
| Date of Latest Transaction | 2026-10-30 |
| Buy/Sell | sell |
| Transaction Count | 13 |
| Shares Transacted | 9,500 |
| Price | $600.09 |
| Total Transaction Value | $5,700,856.23 |
| Insider | |
| Ticker Symbol | UTHR |
| Company | UNITED THERAPEUTICS Corp |
| Insider Name | ROTHBLATT MARTINE A |
| Insider Title | Chairperson & CEO |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 324,443 |
| Position Size Change | 2.84% |
| Filing | |
| Filing Date | 2026-11-02 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were sales of United Therapeutics (UTHR) shares, reported with transaction code S. The filing lists 13 transactions by one insider.
What was the average price of the transaction?
The average sale price was $600.09 per share for the 9,500 shares sold.
How did this transaction affect the insider's holdings?
Martine A. Rothblatt sold 9,500 shares and reported 324,443 shares owned afterward. The shares sold made up 2.84% of the shares owned before the sales.
What's the total transaction value?
The total value of the 13 reported sales was $5,700,856.23.
Are there any special circumstances around this transaction?
The available transaction information identifies a Rule 10b5-1 trading-plan reference. These plans set trading instructions in advance. No footnote text or plan terms are available to confirm which of the 13 sales the reference covers. The plan's start date and trading schedule are unknown. The reference alone does not confirm that the plan met the rule's conditions or explain the reason for the sales.
For research purposes only; not investment advice.